BR112022017240A2 - Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório - Google Patents

Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório

Info

Publication number
BR112022017240A2
BR112022017240A2 BR112022017240A BR112022017240A BR112022017240A2 BR 112022017240 A2 BR112022017240 A2 BR 112022017240A2 BR 112022017240 A BR112022017240 A BR 112022017240A BR 112022017240 A BR112022017240 A BR 112022017240A BR 112022017240 A2 BR112022017240 A2 BR 112022017240A2
Authority
BR
Brazil
Prior art keywords
compositions
treatment
bacterial strains
viral infections
oral use
Prior art date
Application number
BR112022017240A
Other languages
English (en)
Inventor
Biffi Andrea
FIORE Walter
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT102020000005011A external-priority patent/IT202000005011A1/it
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of BR112022017240A2 publication Critical patent/BR112022017240A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

CEPAS BACTERIANAS E COMPOSIÇÕES DAS MESMAS PARA USO ORAL NO TRATAMENTO DE INFECÇÕES VIRAIS DO SISTEMA RESPIRATÓRIO. A presente invenção refere-se a cepas bacterianas e composições das mesmas para uso no tratamento de infecções virais do trato respiratório, de preferência por coronavírus, por exemplo um coronavírus da síndrome respiratória aguda grave (COVID-19), ao estimular e/ou modular citocinas e/ou marcadores envolvidos nos processos inflamatórios das ditas infecções virais do trato respiratório).
BR112022017240A 2020-03-09 2021-03-09 Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório BR112022017240A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102020000005011A IT202000005011A1 (it) 2020-03-09 2020-03-09 Lattoferrina per uso orale ad azione antivirale
IT202000006205 2020-03-24
PCT/IB2021/051954 WO2021181272A1 (en) 2020-03-09 2021-03-09 Bacterial strains and compositions thereof for oral use in the treatment of viral infections of the respiratory system

Publications (1)

Publication Number Publication Date
BR112022017240A2 true BR112022017240A2 (pt) 2022-10-18

Family

ID=75377833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017240A BR112022017240A2 (pt) 2020-03-09 2021-03-09 Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório

Country Status (10)

Country Link
US (1) US20230098743A1 (pt)
EP (1) EP4117696A1 (pt)
JP (1) JP2023517328A (pt)
CN (1) CN115666606A (pt)
AU (1) AU2021235399A1 (pt)
BR (1) BR112022017240A2 (pt)
CA (1) CA3174731A1 (pt)
IL (1) IL295526A (pt)
MX (1) MX2022010877A (pt)
WO (1) WO2021181272A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110897166B (zh) * 2019-09-30 2023-05-09 内蒙古伊利实业集团股份有限公司 具有促消化功效的含益生菌与酪蛋白磷酸肽的食用组合物
AU2022420738A1 (en) * 2021-12-20 2024-05-30 Société des Produits Nestlé S.A. Secretory iga-biotic complexes and uses thereof
WO2023204234A1 (ja) * 2022-04-20 2023-10-26 株式会社 明治 抗ヒトコロナウイルス用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090196921A1 (en) * 2008-02-06 2009-08-06 The Procter & Gamble Company Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition
IT1392672B1 (it) * 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
KR101235561B1 (ko) * 2010-12-09 2013-03-21 주식회사 제일바이오 항바이러스 및 항균 활성을 갖는 락토바실러스 플란타룸 ｃｌｐ-1 균주 및 이를 포함하는 생균제
WO2016030504A1 (en) * 2014-08-29 2016-03-03 Chr. Hansen A/S Probiotic bifidobacterium adolescentis strains

Also Published As

Publication number Publication date
CA3174731A1 (en) 2022-09-07
MX2022010877A (es) 2023-01-04
CN115666606A (zh) 2023-01-31
US20230098743A1 (en) 2023-03-30
IL295526A (en) 2022-10-01
WO2021181272A1 (en) 2021-09-16
AU2021235399A1 (en) 2022-09-08
JP2023517328A (ja) 2023-04-25
EP4117696A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
BR112022017308A2 (pt) Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral
DK2315580T3 (da) Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
CY1113283T1 (el) Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
WO2022015573A8 (en) Sars-cov-2 antigen-binding proteins and uses thereof
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
MX2022013722A (es) Cisteamina para el tratamiento de infección por sars-cov-2.
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
BR112022021423A2 (pt) Uso de proteína surfactante d para tratar infecções virais
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112022005345A2 (pt) Composições imunogênicas
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
WO2019155360A3 (en) Pharmaceutical composition for treating bacterial and viral infections
AU2018257122A1 (en) Pharmaceutical composition comprising attenuated streptococcus pneumoniae strains and use thereof
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
BR112022019876A2 (pt) Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas
MX2022008036A (es) Nuevo uso de formulacion inmunogenica bcg que expresa una proteina de virus respiratorio sincicial contra hmpv.
WO2020132603A3 (en) Salicyl-adenosinemonosulfamate analogs and uses thereof
WO2022099187A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
WO2023183820A3 (en) Respiratory tract infection therapeutics against covid-19